Естонија - Естонски - Ravimiamet

wirtschaftsgenossenschaft deutscher tieraerzte eg - propentofülliin - õhukese polümeerikattega tablett - 50mg 56tk

Естонија - Естонски - Ravimiamet

wirtschaftsgenossenschaft deutscher tieraerzte eg - propentofülliin - õhukese polümeerikattega tablett - 100mg 140tk

Естонија - Естонски - Ravimiamet

krka, d.d., novo mesto - robenakoksiib - närimistablett - 5mg 30tk; 5mg 10tk; 5mg 60tk

Естонија - Естонски - Ravimiamet

krka, d.d., novo mesto - robenakoksiib - närimistablett - 10mg 30tk; 10mg 60tk; 10mg 10tk

Естонија - Естонски - Ravimiamet

krka, d.d., novo mesto - robenakoksiib - närimistablett - 40mg 60tk; 40mg 10tk

Естонија - Естонски - Ravimiamet

krka, d.d., novo mesto - robenakoksiib - närimistablett - 20mg 60tk; 20mg 10tk

Естонија - Естонски - Ravimiamet

krka d.d. novo mesto - maropitant - süstelahus - 10mg 1ml 20ml 1tk

Естонија - Естонски - Ravimiamet

orion corporation - ketoprofeen - süstelahus - 100mg 1ml 50ml 1tk; 100mg 1ml 100ml 10tk; 100mg 1ml 50ml 10tk

Европска Унија - Естонски - EMA (European Medicines Agency)

viatris healthcare limited - imikvimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiootikumid ja kemoterapeutikumid dermatoloogiliseks kasutamiseks - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Европска Унија - Естонски - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.